Welcome to HitGen

News

Get up to date with the latest HitGen articles and join us in the events

  1. News
  2. Press Release

Press Release

  • 06 April 2022
    HitGen and UPPTHERA Extend PROTAC Research Collaboration after Hit Finding Success on Undruggable Targets
    CHENGDU, China, April 6, 2022 – HitGen Inc. (“HitGen”), a Shanghai Stock Exchange STAR-listed company, today announced that the company has successfully completed the multiple-target drug discovery research projects with UPPTHERA, a Korean pharmaceutical company aiming for new drug development employing “Protein Degradation Technology”. During the collaboration, multiple undisclosed targets were screened against HitGen’s proprietary over 1 trillion DNA-encoded libraries (DELs). The majority of the targets have resulted in confirmed hits, which have high potential for PROTAC development. Now the two parties are extending the collaboration on further development of these projects and additional challenging targets.
  • 21 March 2022
    In February 2022, HitGen Inc. signed an agreement with Eli Lilly and ConfometRx to begin work on a GPCR target.
    In February 2022, HitGen Inc. signed an agreement with Eli Lilly and ConfometRx to begin work on a GPCR target.
  • 21 March 2022
    Lipigon and HitGen announce achievement of an important milestone in dyslipidemia project
    Lipigon Pharmaceuticals AB ("Lipigon") and HitGen Inc. (“HitGen”) today announced that they have identified novel small molecules that could be starting points for developing drugs targeting dyslipidemia and cardiovascular disease.
  • 17 March 2022
    HitGen Announces Research Collaboration Focused on DNA-Encoded Library Based Drug Discovery
    CHENGDU, China, March 17, 2022 – Shanghai Stock Exchange listed company HitGen Inc. (“HitGen”) today announced that it has entered into a research collaboration agreement with Howard Hughes Medical Institute (“HHMI”) and Duke University. The Principal Investigators for HHMI and Duke University who will oversee the collaboration will be Dr. Robert J. Lefkowitz, a James B. Duke Professor of Medicine and Professor of Biochemistry and Chemistry at the Duke University Medical Center,
  • 25 February 2022
    HitGen has successfully completed a three-year collaboration with MTPC to discover novel hit compounds for multiple drug targets
    Chengdu, China, February 25, 2022 – HitGen Inc. (“HitGen”), a Shanghai Stock Exchange STAR-listed company, today announced that the company has successfully completed a three-year drug discovery research collaboration with Mitsubishi Tanabe Pharma Corporation (“MTPC”), a Japanese pharmaceutical company with the mission of “Creating hope for all facing illness”.
  • 23 December 2021
    Lipigon and HitGen extend collaboration agreement on dyslipidemia project
    Chengdu, China December 23, 2021 Lipigon Pharmaceuticals AB (”Lipigon”), developer of therapeutics for lipid-related diseases, and HitGen Inc. (”HitGen”) have extended the collaboration agreement on the development of small molecules for the treatment of dyslipidemia and cardiometabolic disease until 7 July 2024.
  • 05 November 2021
    HitGen and Cambridge Molecular announce a strategic partnership, bringing together DNA-Encoded Libraries and Deep Learning
    Chengdu, China, and Cambridge, United Kingdom, 5 November 2021 – HitGen Inc. (688222.SH) and Cambridge Molecular are pleased to announce an exclusive alliance, introducing DeepDELve 2 – Cambridge Molecular’s highly optimised DEL-specific deep learning system – as an addition to HitGen’s world-leading DEL discovery platform, with over 1 trillion drug-like small molecules.
  • 01 November 2021
    Vernalis Research - a fully owned subsidiary of HitGen Inc - and Hannibal Innovation announce the creation of Dania Therapeutics ApS
    Chengdu, China, 1 November 2021 – Vernalis Research (“Vernalis”), a fully owned subsidiary of HitGen Inc., and Hannibal Innovation ApS (“Hannibal”) are pleased to announce the creation of Dania Therapeutics ApS (“Dania”) to discover small molecules inhibitors against new undisclosed oncology targets.
  • 29 October 2021
    Infographic|HitGen FY2021 Q3 Report
    Infographic|HitGen FY2021 Q3 Report
  • 02 September 2021
    Veritas In Silico and HitGen Announce Research Collaboration Focused on DNA-Encoded Library Based RNA-targeting small molecule Drug Discovery
    CHENGDU, China, Sep 2nd, 2021-- Shanghai Stock Exchange listed company HitGen Inc. (“HitGen”) and Veritas In Silico Inc. (“Veritas In Silico”), a Tokyo-based private company, today announced that they have entered into a research collaboration agreement to discover small molecule compounds against RNA targets. Veritas In Silico will apply its drug discovery platform, ibVIS, to identify certain RNA targets that are of interest to Veritas In Silico.

Questions?

For more details on how we can advance your innovative drug discovery projects
By submitting your information, you acknowledge having received, read and understood our Privacy Notice as made available above.

We use cookies to provide a better web experience.
By using our site, you acknowledge our use of cookies and please read our Cookie Notice for More information